Rigel Pharmaceuticals Valuation
| RIGL Stock | USD 20.20 0.17 0.83% |
At this time, the company appears to be fairly valued. Rigel Pharmaceuticals holds a recent Real Value of $20.26 per share. The prevailing price of the company is $20.2. Our model determines the value of Rigel Pharmaceuticals from analyzing the company fundamentals such as Operating Margin of 0.29 %, return on equity of -6.99, and Shares Outstanding of 17.86 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Rigel Pharmaceuticals' valuation include:
Price Book 109.742 | Enterprise Value | Enterprise Value Ebitda 12.0467 | Price Sales 2.0127 | Forward PE 22.9358 |
Fairly Valued
Today
Please note that Rigel Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Rigel Pharmaceuticals is based on 3 months time horizon. Increasing Rigel Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Rigel stock is determined by what a typical buyer is willing to pay for full or partial control of Rigel Pharmaceuticals. Since Rigel Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rigel Stock. However, Rigel Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20.2 | Real 20.26 | Target 31.33 | Hype 20.2 | Naive 19.59 |
The intrinsic value of Rigel Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Rigel Pharmaceuticals' stock price.
Estimating the potential upside or downside of Rigel Pharmaceuticals helps investors to forecast how Rigel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rigel Pharmaceuticals more accurately as focusing exclusively on Rigel Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Rigel Pharmaceuticals' intrinsic value based on its ongoing forecasts of Rigel Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Rigel Pharmaceuticals' closest peers.
Rigel Pharmaceuticals Cash |
|
Rigel Valuation Trend
Knowing Rigel Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Rigel Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Rigel Revenue by Product
Rigel Pharmaceuticals Total Value Analysis
Rigel Pharmaceuticals is at this time forecasted to have valuation of 343.48 M with market capitalization of 360.83 M, debt of 59.97 M, and cash on hands of 81.64 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rigel Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
343.48 M | 360.83 M | 59.97 M | 81.64 M |
Rigel Pharmaceuticals Investor Information
About 69.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Rigel Pharmaceuticals had 1:10 split on the 27th of June 2024. Based on the key indicators related to Rigel Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Rigel Pharmaceuticals is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in April.Rigel Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Rigel Pharmaceuticals has an asset utilization ratio of 109.33 percent. This suggests that the Company is making $1.09 for each dollar of assets. An increasing asset utilization means that Rigel Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Rigel Pharmaceuticals Ownership Allocation
Rigel Pharmaceuticals owns a total of 17.86 Million outstanding shares. Over half of Rigel Pharmaceuticals' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Rigel Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 179.28 M. Net Income was 17.48 M with profit before overhead, payroll, taxes, and interest of 137.25 M.About Rigel Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Rigel Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Rigel Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Rigel Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Rigel Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Rigel Pharmaceuticals. We calculate exposure to Rigel Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rigel Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 160.6 M | 168.7 M | |
| Pretax Profit Margin | 0.10 | 0.11 | |
| Operating Profit Margin | 0.13 | 0.14 | |
| Net Profit Margin | 0.10 | 0.10 | |
| Gross Profit Margin | 0.90 | 0.94 |
Rigel Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Rigel Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 17.7 M | |
| Quarterly Earnings Growth Y O Y | 17.867 | |
| Forward Price Earnings | 22.9358 |
Rigel Pharmaceuticals Current Valuation Indicators
Rigel Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Rigel Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Rigel Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Rigel Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Rigel Pharmaceuticals' worth.When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 17.867 | Earnings Share 0.99 | Revenue Per Share | Quarterly Revenue Growth 0.609 | Return On Assets |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.